Biohaven Ltd. (BHVN) Form 8-K — Oct 15, 2026
Biohaven has entered a Collaboration and License Agreement with Ono Pharmaceutical granting Ono exclusive rights to develop and commercialize its MoDE pan IgG degrader portfolio — led by Phase 3 Graves' disease candidate BHV-1300, plus follow-ons BHV-1310 and BHV-1320 — in Japan, South Korea, Taiwan and ASEAN countries. Ono will pay Biohaven an $80 million upfront payment upon closing plus a $20 million payment upon a milestone achievement, and royalties of approximately 20% on net sales in the licensed territory. Biohaven retains all rights outside the licensed territory, including the US, Europe and China.
Key figures
- Royalty Rate
- approximately 20%
- Upfront Payment
- 80000000
- Milestone Payment
- 20000000
- Licensed Territory
- Japan, South Korea, Taiwan and ASEAN countries
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.